Bictegravir-containing regimens performed well over 48 weeks, with more than 90% of participants achieving a viral load less than 50 copies/mL.
The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.
A recent clinical trial found that doravirine was roughly equivalent in potency to darunavir-based regimens.
At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.
A capsid inhibitor could affect three parts of HIV's life cycle and could be used by itself in the prevention of HIV infection. However, much work lies ahead before this drug's developer can be certain about that.
In a small cross-sectional study researchers found a link between the use of integrase inhibitors and the presence of low testosterone, but they may have inadvertently arrived at this conclusion.
Two cohort studies presented at CROI 2017 showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.
New research shows that it may be possible to identify many latently infected CD4 T cells due to expression of a particular cell surface protein.
One injection of long-acting cabotegravir (CAB LA) protected 21 of 24 macaques from intravenous challenge with simian immunodeficiency virus (SIV).
Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone.